BioCardia (BCDA) Research & Development (2016 - 2026)

BioCardia (BCDA) has reported Research & Development for 11 consecutive years, with $893000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 34.72% year-over-year to $893000.0 in Q2 2026; TTM through Jun 2026 was $4.4 million, a 15.48% decrease from a year earlier, with the FY2024 full-year figure at $4.4 million, down 43.22% from the prior year.
• Research & Development was $893000.0 for Q2 2026 at BioCardia, down from $1.2 million in the prior quarter.
• Over five years, Research & Development peaked at $2.4 million in Q1 2023 and troughed at $800000.0 in Q2 2024.
• A 5-year average of $1.6 million and a median of $1.4 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development sank 65.43% in 2024 and soared 71.0% in 2025, its largest moves.
• Over 5 years, Research & Development stood at $2.2 million in 2022, then tumbled by 47.45% to $1.2 million in 2023, then climbed by 22.4% to $1.4 million in 2024, then sank by 33.85% to $936000.0 in 2025, then decreased by 4.59% to $893000.0 in 2026.
• The last three Research & Development figures came in at $893000.0 (Q2 2026), $1.2 million (Q1 2026), and $936000.0 (Q3 2025), per Business Quant data.